scholarly journals TCT-427 Renal Denervation Improves Renal Hemodynamic Status in Patients With Diabetes With Resistant Hypertension and Chronic Kidney Disease

2021 ◽  
Vol 78 (19) ◽  
pp. B175-B176
Author(s):  
Musheg Manukyan ◽  
Alla Falkovskaya ◽  
Stanislav Pekarskiy ◽  
Irina Zyubanova ◽  
Ekaterina Tsoi ◽  
...  
2012 ◽  
Vol 30 ◽  
pp. e90
Author(s):  
Marcio Kiuchi ◽  
George Maia ◽  
Jocemir Lugon ◽  
Maria Angela Carreira ◽  
Tetsuaki Kiuchi ◽  
...  

2013 ◽  
Vol 34 (28) ◽  
pp. 2114-2121 ◽  
Author(s):  
Márcio Galindo Kiuchi ◽  
George Luiz Marques Maia ◽  
Maria Angela Magalhães de Queiroz Carreira ◽  
Tetsuaki Kiuchi ◽  
Shaojie Chen ◽  
...  

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
M Manukyan ◽  
A Falkovskaya ◽  
V Mordovin ◽  
S Pekarskiy ◽  
I Zyubanova ◽  
...  

Abstract Background There are very few data on the initial features of hemodynamics and its changes after renal denervation (RDN) in patients with resistant hypertension (RHTN) and type 2 diabetes mellitus (DM), depending on the presence of chronic kidney disease (CKD), and the mechanisms of this effect require further study. Purpose To assess the features of renal hemodynamics and its change after RDN in patients with RHTN with type 2 DM, depending on the presence or absence of CKD. Methods In the study were included 38 patients with RHTN with type 2 DM (mean age 60.6±8.1 years, 14 men, 24-hour systolic / diastolic blood pressure (24-hr SBP/DBP) 160.9±16.5 / 82.2±11.3 mm Hg, mean HbA1c 7.87±1.62%), of which CKD occurred in 18 pts. (eGFR – 47.1 ml/min/1.73 m2), and 20 pts. without CKD (eGFR – 80.3 ml/min/1.73m2). All patients underwent baseline office and 24-hr BP measurement with calculation DBP/SBP ratio (D/S ratio), Doppler ultrasonography, serum creatinine, estimated glomerular filtration rate (eGFR) (CKD-EPI formula), urinary albumin excretion (UAE). The six-month follow-up period was completed by 14 patients in the group with CKD and 18 patients without CKD. Results At baseline, patients with CKD compared with those without CKD had higher pulse BP (82.2±10.0 versus 75.6±15.9, p=0.061), renal resistive indices (RRI) (0.78±0.06 versus 0.69±0.05, p=0.001 in the main renal arteries (RA); 0.73±0.07 versus 0, 63±0.06, p=0.001 in segmental RA) and significantly lower level of D/S ratio (0.49±0.06 versus 0.53±0.06, p=0.040). At the same time, the frequency of increased RRI (>0.70) in the CKD group was almost 14 times higher than in those without CKD (73% and 5.3%, respectively, p<0.001).After RDN, patients with CKD showed a significant decrease in SBP (−10.7 mm Hg, p=0.008) and an insignificant decrease in DBP (−3.9 mm Hg, p=0.118). In group without CKD, on the contrary, there was an insignificant decrease in SBP (−7.6 mm Hg, p=0.102) and a significant decrease in DBP (−5.5 mm Hg, p=0.030). The D/S ratio tended to increase in the group of CKD patients (p=0.08), whereas these indicators did not change significantly in the group without CKD. Additionally, there were a positive dynamics of RRI (decrease >0.05) in patients with CKD, the frequency of which was almost 4 times higher than that in persons without CKD (43% and 11%, respectively, p=0.049). Moreover, a decrease in RRI correlated with an increase in the D / S ratio of both the main RA (R = 0.50; p=0.005) and in segmental RA (R = 0.40; p=0.028). There were no significant changes in UAE and serum creatinine in both groups. Conclusions Thus, CKD in patients with RHTN with type 2 DM is characterized by a significant increase in renal vascular resistance, while RDN in this patients, in contrast to patients without CKD, can be an effective therapeutic option not only for BP reduction, but also for improvement of renal hemodynamics. FUNDunding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Russian Foundation for Basic Research


2014 ◽  
Vol 19 (3) ◽  
pp. 187-188
Author(s):  
Sergio Morelli ◽  
Gaetano Tanzilli ◽  
Luigina Farina ◽  
Giorgia Rubini ◽  
Giancarlo Ralli ◽  
...  

2015 ◽  
Vol 33 (6) ◽  
pp. 1261-1266 ◽  
Author(s):  
Christian Ott ◽  
Felix Mahfoud ◽  
Axel Schmid ◽  
Stefan W. Toennes ◽  
Sebastian Ewen ◽  
...  

CJC Open ◽  
2020 ◽  
Vol 2 (4) ◽  
pp. 258-264 ◽  
Author(s):  
Marcel Ruzicka ◽  
Greg Knoll ◽  
Frans H.H. Leenen ◽  
Judith Leech ◽  
Shawn D. Aaron ◽  
...  

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Demetria Hubbard ◽  
Lisandro D. Colantonio ◽  
Robert S. Rosenson ◽  
Todd M. Brown ◽  
Elizabeth A. Jackson ◽  
...  

Abstract Background Adults who have experienced multiple cardiovascular disease (CVD) events have a very high risk for additional events. Diabetes and chronic kidney disease (CKD) are each associated with an increased risk for recurrent CVD events following a myocardial infarction (MI). Methods We compared the risk for recurrent CVD events among US adults with health insurance who were hospitalized for an MI between 2014 and 2017 and had (1) CVD prior to their MI but were free from diabetes or CKD (prior CVD), and those without CVD prior to their MI who had (2) diabetes only, (3) CKD only and (4) both diabetes and CKD. We followed patients from hospital discharge through December 31, 2018 for recurrent CVD events including coronary, stroke, and peripheral artery events. Results Among 162,730 patients, 55.2% had prior CVD, and 28.3%, 8.3%, and 8.2% had diabetes only, CKD only, and both diabetes and CKD, respectively. The rate for recurrent CVD events per 1000 person-years was 135 among patients with prior CVD and 110, 124 and 171 among those with diabetes only, CKD only and both diabetes and CKD, respectively. Compared to patients with prior CVD, the multivariable-adjusted hazard ratio for recurrent CVD events was 0.92 (95%CI 0.90–0.95), 0.89 (95%CI: 0.85–0.93), and 1.18 (95%CI: 1.14–1.22) among those with diabetes only, CKD only, and both diabetes and CKD, respectively. Conclusion Following MI, adults with both diabetes and CKD had a higher risk for recurrent CVD events compared to those with prior CVD without diabetes or CKD.


2007 ◽  
Vol 85 (1) ◽  
pp. 96-101 ◽  
Author(s):  
Christelle Raffaitin ◽  
Catherine Lasseur ◽  
Philippe Chauveau ◽  
Nicole Barthe ◽  
Henri Gin ◽  
...  

Anemia ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Geoffrey Teehan ◽  
Robert L. Benz

Background. Erythropoietin deficiency and anemia occur in Chronic Kidney Disease (CKD) and may be treated with Erythropoietin Stimulating Agents (ESAs). The optimal hemoglobin, in non-End Stage Renal Disease CKD, is controversial.Methods. We review three recent randomized trials in anemia in CKD: CHOIR, CREATE, and TREAT.Results. CHOIR (N=1432) was terminated early with more frequent death and cardiovascular outcomes in the higher Hb group (HR 1.34: 95% C.I. 1.03–1.74,P=.03). CREATE (N=603) showed no difference in primary cardiovascular endpoints. Stroke was more common in the higher Hb group (HR 1.92; 95% C.I. 1.38–2.68;P<.001) in TREAT (N=4038).Conclusions. There is no benefit to an Hb outside the 10–12 g/dL range in this population. To avoid transfusions and improve Quality of Life, ESAs should be used cautiously, especially in patients with Diabetes, CKD, risk factors for stroke, and ESA resistance.


2017 ◽  
Vol 35 ◽  
pp. e49
Author(s):  
C. Ott ◽  
F. Mahfoud ◽  
G. Mancia ◽  
K. Narkiewicz ◽  
L.M. Ruilope ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document